Evidence map›Paper›PMID 30859896›Full record

ArticleJournal of the American Heart Association2019

Association Between Serum High-Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOW-CKD.

Ki Heon Nam, Tae Ik Chang, Young Su Joo, Joohwan Kim, Sangmi Lee, Changhyun Lee, Hae-Ryong Yun, Jung Tak Park, Tae-Hyun Yoo, Su Ah Sung and 9 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ki Heon Nam1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Tae Ik Chang4 Department of Internal Medicine National Health Insurance Service Medical Center Ilsan Hospital Goyang-si Gyeonggi-do Korea.
Young Su Joo1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Joohwan Kim1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Sangmi Lee1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Changhyun Lee1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Hae-Ryong Yun1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Jung Tak Park1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Tae-Hyun Yoo1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Su Ah Sung5 Department of Internal Medicine Eulji General Hospital Eulji School of Medicine Seoul Korea.
Kyu-Beck Lee6 Department of Internal Medicine Sungkyunkwan University School of Medicine Kangbuk Samsung Hospital Seoul Korea.
Kook-Hwan Oh7 Department of Internal Medicine Seoul National University Hospital Seoul Korea.
Soo Wan Kim8 Department of Internal Medicine Chonnam National University Hospital and Medical School Gwangju Korea.
Joongyub Lee9 Department of Prevention and Management Inha University School of Medicine Incheon Korea.
Shin-Wook Kang1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Kyu Hun Choi1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Curie Ahn7 Department of Internal Medicine Seoul National University Hospital Seoul Korea.
Seung Hyeok Han1 Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
KNOW‐CKD (KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease) Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background High-density lipoprotein cholesterol ( HDL -C) levels are generally decreased in patients with chronic kidney disease ( CKD ). However, studies on the relationship between HDL -C and CKD progression are scarce. Methods and Results We studied the association between serum HDL -C levels and the risk of CKD progression in 2168 participants of the KNOW - CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease). The primary outcome was the composite of a 50% decline in estimated glomerular filtration rate from baseline or end-stage renal disease. The secondary outcome was the onset of end-stage renal disease. During a median follow-up of 3.1 (interquartile range, 1.6-4.5) years, the primary outcome occurred in 335 patients (15.5%). In a fully adjusted Cox model, the lowest category with HDL -C of <30 mg/dL (hazard ratio, 2.21; 95% CI, 1.30-3.77) and the highest category with HDL -C of ≥60 mg/dL (hazard ratio, 2.05; 95% CI , 1.35-3.10) were associated with a significantly higher risk of the composite renal outcome, compared with the reference category with HDL -C of 50 to 59 mg/dL. This association remained unaltered in a time-varying Cox analysis. In addition, a fully adjusted cubic spline model with HDL -C being treated as a continuous variable yielded similar results. Furthermore, consistent findings were obtained in a secondary outcome analysis for the development of end-stage renal disease. Conclusions A U-shaped association was observed between serum HDL -C levels and adverse renal outcomes in this large cohort of patients with CKD . Our findings suggest that both low and high serum HDL -C levels may be detrimental to patients with nondialysis CKD .

Indexed as

BiomarkersCholesterol, HDLDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRenal Insufficiency, ChronicRisk FactorsBiomarkersCholesterol, HDLchronic kidney diseasehigh‐density lipoproteinhigh‐density lipoprotein cholesterolkidneykidney disease progression

Identifiers

PMID30859896
PMCPMC6475054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.